Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine repeated doses

Spotlight: Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."
Michael DeMarco, PhD

by Michael DeMarco, PhD

Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial - PubMed
<span><b>Objective:</b> Electroconvulsive therapy (ECT) has potent antidepressant effects yet can lead to neurocognitive side effects. Ketamine is a rapid-acting antidepressant, which may be an alternative to ECT. Few have directly compared the cognitive effects of ECT and ketamine treatment. <b>Methods:</b></span> …
PubMedKristina T Kumpf

Comparación de los efectos cognitivos de la ketamina intravenosa repetida y la terapia electroconvulsiva en pacientes con depresión resistente en tratamiento: Análisis secundario del ensayo ELEKT-D

Los pacientes tratados con ketamina demostraron un funcionamiento cognitivo superior en comparación con la TEC después de un tratamiento de 3 semanas, sin diferencias entre los tratamientos observados. Los hallazgos apoyan la superioridad a corto plazo de la ketamina sobre el funcionamiento cognitivo y la seguridad cognitiva a largo plazo de ambos tratamientos.

More like this

Spotlight: Single Treatment With MM120 (Lysergide) in Generalized Anxiety DisorderA Randomized Clinical Trial (Robinson, et al, 2025)

In this phase 2b, multicenter, randomized, double-blind, placebo-controlled study of 4 dose levels of MM120 (a form of LSD) that included 198 adults with generalized anxiety disorder 4 was statistically significant.

Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

Spotlight: Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial (McGowan, et al, 2025)

"In this trial, COMP360 psilocybin administered in a single session with psychological support was found to be generally well-tolerated and without serious risk to safety... treatment associated with rapid, sustained reduction in PTSD symptoms, improved functioning and quality of life to 12 weeks"

Spotlight: Brain changes associated with depression treatment: a meta-analysis

Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.

Spotlight: NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review (Badrfam, et al, 2025)

"Ketamine infusions have improved processing speed and verbal learning in bipolar disorder patients. Evidence suggests that NMDA receptor-modulating agents play a significant role in improving cognitive function in patients with bipolar disorder. "

Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)

Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
Mastodon Mastodon